Get the content you want anytime you want.

Top 5 Contagion® News Articles for the Week of November 19, 2017


#5: Drug-Resistant Strains of Gonorrhea Spreads to North America

The incidence of drug-resistant gonorrhea infections has grown in the past several years; however, the majority of these infections have been reported outside of North America. Until now. According to a recent dispatch from the Centers for Disease Control and Prevention (CDC), a drug-resistant strain of Neisseria gonorrhoeae (N. gonorrhoeae ) was found in Canada this year.

As Contagion® reported in July 2017, gonorrhea, a sexually-transmitted disease caused by N. gonorrhoeae bacteria, is on its way to becoming untreatable. According to the World Health Organization (WHO) Global Gonococcal Antimicrobial Surveillance Programme (WHO GASP), an estimated 78 million individuals are infected with gonorrhea on an annual basis, and the number of cases that are resistant to currently available antibiotics continues to grow. Teodora Wi, MD, Medical Officer, Human Reproduction at WHO, explained in a news release, “The bacteria that cause gonorrhea are particularly smart. Every time we use a new class of antibiotics to treat the infection, the bacteria evolve to resist them.”

Read more about antibiotic-resistant gonorrhea here.

#4: No Benefits for Protease Inhibitor Plus Raltegravir As Second Line HIV

A recent study showed that treatment with a protease inhibitor plus raltegravir offered no benefit over a protease inhibitor plus nucleoside reverse-transcriptase inhibitor (NRTI) regimen in patients with HIV.

James G. Hakim, MD, from the University of Zimbabwe Clinical Research Centre, Harare, and colleagues published the results of their study November 3, 2017, in the Lancet Infectious Diseases.

Read more here.

Big advances in treatment can